Ovarian protection before gonadotoxic therapy is a problem of oncology and reproductive medicine

DOI

https://dx.doi.org/10.18565/aig.2020.11.13-19

Dmitrieva I.E., Nazarenko T.A., Khokhlova S.V.
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

Anticancer chemotherapy is one of the main treatments for cancers. Moreover, in addition to its high efficiency, the chemotherapy has a gonadotoxic effect that worsens quality of life in patients, most of whom are reproductive aged at the time of diagnosis. The review includes data from Russian and foreign articles published in the PubMed database over the past 5 years. To reduce the pathological effect of anticancer therapy on the ovaries, several categories of drugs (gonadotropin-releasing hormone agonists, continuous oral contraceptives) are used. The efficacy of these drugs in preserving the reproductive and endocrine functions of the ovaries has not yet been proven. That is the reason that the search for new agents to protect the ovaries is now underway. The degree of damage to the ovarian reserve during treatment and the efficiency of ovarian protection are known to depend on many factors. Nevertheless, prescribing criteria and tactics have not been developed even for already existing drugs.
Conclusion. This scientific literature review shows that it is necessary to assess the clinical significance of the methods used to protect the ovaries and to elaborate new approaches.

oncofertility

ovarian protection

fertility preservation

Full text (in Russian)

Каприн А.Д., Старинский В.В., Шахзадова А.О., ред. Состояние онкологической помощи населению России в 2019 году. М.: МНИОИим. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2020. 239с. [State of cancer care in Russia in 2019. Ed. by A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. M.: Herzen Moscow State Medical Research Institute branch of the Federal State Budgetary Institution "NMIC of radiology" of the Ministry of Health of Russia. 2020; 239 p. (in Russian)].
Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019; 69(1): 7‐34. https://dx.doi.org/10.3322/caac.21551.
Ruggeri M., Pagan E., Bagnardi V., Bianco N., Gallerani E., Buser K. et al. Fertility concerns, preservation strategies and quality of life in young women with breast cancer: baseline results from an ongoing prospective cohort study in selected European Centers. Breast. 2019; 47: 85‐92. https://dx.doi.org/10.1016/j.breast.2019.07.001.
Kreuser E.D., Hetzel W.D., Billia D.O., Thiel E. Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treat. Rev. 1990; 17(2-3): 169‐75. https://dx.doi.org/10.1016/0305-7372(90)90043-f.
Howard-Anderson J., Ganz P.A., Bower J.E., Stanton A.L. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J. Natl. Cancer Inst. 2012; 104(5): 386‐405. https://dx.doi.org/doi:10.1093/jnci/djr541.
Smith K.L., Gracia C., Sokalska A., Moore H. Advances in fertility preservation for young women with cancer. Am. Soc. Clin. Oncol. Educ. Book. 2018; 38: 27‐37. https://dx.doi.org/10.1200/EDBK_208301.
Kim S.S., Donnez J., Barri P., Pellicer A., Patrizio P., Rosenwaks Z. et al.; ISFP Practice Committee. Recommendations for fertility preservation in patients with lymphoma, leukemia, and breast cancer. J. Assist. Reprod. Genet. 2012; 29(6): 465‐8. https://dx.doi.org/10.1007/s10815-012-9786-y.
Peccatori F.A., Azim H.A.Jr., Orecchia R., Hoekstra H.J., Pavlidis N., Kesic V. et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24(Suppl. 6): vi160‐vi170. https://dx.doi.org/10.1093/annonc/mdt199.
Paluch-Shimon S., Cardoso F., Partridge A.H., Abulkhair O., Azim H.A. Jr.,Bianchi-Micheli G. et al. ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Ann. Oncol. 2020;S0923-7534(20)36363-8. https://dx.doi.org/10.1016/j.annonc.2020.03.284.
Brydøy M., Fosså S.D., Dahl O., Bjøro T. Gonadal dysfunction and fertility problems in cancer survivors. Acta Oncol. 2007; 46(4): 480‐9. https://dx.doi.org/10.1080/02841860601166958.
Bedaiwy M.A., Abou-Setta A.M., Desai N., Hurd W., Starks D., El-Nashar S.A. et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil. Steril. 2011; 95(3): 906‐14. e144. https://dx.doi.org/10.1016/j.fertnstert.2010.11.017.
Zavos A., Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncol. 2016; 55(6): 664‐70. https://dx.doi.org/10.3109/0284186X.2016.1155738.
Zhong Y., Lin Y., Cheng X., Huang X., Zhou Y., Mao F. et al. GnRHa for ovarian protection and the association between AMH and ovarian function during adjuvant chemotherapy for breast cancer. J. Cancer. 2019; 10(18): 4278‐85. https://dx.doi.org/10.7150/jca.31859.
Broer S.L., Broekmans F.J., Laven J.S., Fauser B.C. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum. Reprod. Update. 2014; 20(5): 688‐701. https://dx.doi.org/10.1093/humupd/dmu020.
Fréour T., Barrière P., Masson D. Anti-müllerian hormone levels and evolution in women of reproductive age with breast cancer treated with chemotherapy. Eur. J. Cancer. 2017; 74: 1‐8. https://dx.doi.org/10.1016/j.ejca.2016.12.008.
Anderson R.A., Mansi J., Coleman R.E., Adamson D.J.A., Leonard R.C.F. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur. J. Cancer. 2017; 87: 58‐64. https://dx.doi.org/10.1016/j.ejca.2017.10.001.
Oktay K., Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue N. Engl. J. Med. 2000; 342(25): 1919. https://dx.doi.org/10.1056/NEJM200006223422516.
Wang X., Chen H., Yin H., Kim S.S., Lin Tan S., Gosden R.G. Fertility after intact ovary transplantation. Nature. 2002; 415(6870): 385. https://dx.doi.org/10.1038/415385a.
Martinez-Madrid B., Dolmans M.M., Van Langendonckt A., Defrère S., Donnez J. Freeze-thawing intact human ovary with its vascular pedicle with a passive cooling device. Fertil. Steril. 2004; 82(5): 1390‐4. https://dx.doi.org/10.1016/j.fertnstert.2004.06.036.
Martinez F.; International Society for Fertility Preservation–ESHRE–ASRM Expert Working Group. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Fertil. Steril. 2017; 108(3): 407‐415. e11. https://dx.doi.org/10.1016/j.fertnstert.2017.05.024.
Sutcliffe S.B. Cytotoxic chemotherapy and gonadal function in patients with Hodgkin's disease. Facts and thoughts. JAMA. 1979; 242(17): 1898‐9.
Recchia F., Sica G., De Filippis S., Saggio G., Rosselli M., Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs. 2002; 13(4): 417‐24. https://dx.doi.org/10.1097/00001813-200204000-00011.
Blumenfeld Z., Avivi I., Linn S., Epelbaum R., Ben-Shahar M., Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum. Reprod. 1996; 11(8): 1620‐6. https://dx.doi.org/10.1093/oxfordjournals.humrep.a019457.
Kitajima Y., Endo T., Nagasawa K., Manase K., Honnma H., Baba T. et al. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Endocrinology. 2006; 147(2): 694‐9. https://dx.doi.org/10.1210/en.2005-0700.
Imai A., Sugiyama M., Furui T., Tamaya T., Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol. Obstet. Invest. 2007; 63(2): 102‐6. https://dx.doi.org/10.1159/000096062.
Leung P.C., Cheng C.K., Zhu X.M. Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Mol. Cell. Endocrinol. 2003; 202(1-2): 145‐53. https://dx.doi.org/10.1016/s0303-7207(03)00076-5.
Scaruffi P., Stigliani S., Cardinali B., Massarotti C., Lambertini M., Sozzi F. et al. Gonadotropin releasing hormone agonists have an anti-apoptotic effect on cumulus cells. Int. J. Mol. Sci. 2019; 20(23): 6045. https://dx.doi.org/10.3390/ijms20236045.
Francis P.A., Regan M.M., Fleming G.F., Láng I., Ciruelos E., Bellet M. et al. Adjuvant ovarian suppression in premenopausal breast cancer. N. Engl. J. Med. 2015; 372(5): 436‐46. https://dx.doi.org/10.1056/NEJMoa1412379.
Клинические рекомендации. Рак молочной железы. МКБ-10: C50 ID.КР178. 2017. 88 c. [Association of oncologists of Russia. Clinical recommendations: breast Cancer. 2017. 88 р. (in Russian)].
Lambertini M., Boni L., Michelotti A., Gamucci T., Scotto T., Gori S. et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015; 314(24): 2632‐40. https://dx.doi.org/10.1001/jama.2015.17291.
Moore H.C., Unger J.M., Phillips K.A., Boyle F., Hitre E., Porter D. et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N. Engl. J. Med. 2015; 372(10): 923‐32. https://dx.doi.org/10.1056/NEJMoa1413204.
Blumenfeld Z., Dann E. GnRH agonist for the prevention of chemotherapy-induced ovarian failure in lymphoma. J. Clin. Oncol. 2013; 31(29): 3721. https://dx.doi.org/10.1200/JCO.2012.47.8222.
Zhang Y., Ji Y., Li J., Lei L., Wu S., Zuo W. et al. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival. Breast Cancer Res. Treat. 2018; 168(3): 679‐86. https://dx.doi.org/10.1007/s10549-018-4660-y.
Behringer K., Wildt L., Mueller H., Mattle V., Ganitis P., van den Hoonaard B. et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann. Oncol. 2010; 21(10): 2052‐60. https://dx.doi.org/10.1093/annonc/mdq066.
Demeestere I., Brice P., Peccatori F.A., Kentos A., Dupuis J., Zachee P. et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J. Clin. Oncol. 2016; 34(22): 2568‐74. https://dx.doi.org/10.1200/JCO.2015.65.8864.
Behringer K., Thielen I., Mueller H., Goergen H., Eibl A.D., Rosenbrock J. et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann. Oncol. 2012; 23(7): 1818‐25. https://dx.doi.org/10.1093/annonc/mdr575.
Blumenfeld Z., von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum. Reprod. Update. 2008; 14(6): 543‐52. https://dx.doi.org/10.1093/humupd/dmn022.
Bildik G., Akin N., Senbabaoglu F., Sahin G.N., Karahuseyinoglu S., Ince U.et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. Hum. Reprod. 2015; 30(12): 2912‐25. https://dx.doi.org/10.1093/humrep/dev257.
Roness H., Spector I., Leichtmann-Bardoogo Y., Savino A.M., Dereh-Haim S., Meirow D. Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects. J. Assist. Reprod. Genet. 2019; 36(9): 1793‐803. https://dx.doi.org/10.1007/s10815-019-01507-9.
Kim S.Y., Cordeiro M.H., Serna V.A., Ebbert K., Butler L.M., Sinha S. et al. Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network. Cell Death Differ. 2013; 20(8): 987‐97. https://dx.doi.org/10.1038/cdd.2013.31.
Li F., Turan V., Lierman S., Cuvelier C., De Sutter P., Oktay K. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death. Hum. Reprod. 2014; 29(1): 107‐13. https://dx.doi.org/10.1093/humrep/det391.
Akdemir A., Zeybek B., Akman L., Ergenoglu A.M., Yeniel A.O., Erbas O. et al. Granulocyte-colony stimulating factor decreases the extent of ovarian damage caused by cisplatin in an experimental rat model. J. Gynecol. Oncol. 2014; 25(4): 328‐33. https://dx.doi.org/10.3802/jgo.2014.25.4.328.
Hasky N., Uri-Belapolsky S., Goldberg K., Miller I., Grossman H., Stemmer S.M. et al. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma? Hum. Reprod. 2015; 30(5): 1089‐101. https://dx.doi.org/10.1093/humrep/dev037.
Kalich-Philosoph L., Roness H., Carmely A., Fishel-Bartal M., Ligumsky H., Paglin S. et al. Cyclophosphamide triggers follicle activation and "burnout"; AS101 prevents follicle loss and preserves fertility. Sci. Transl. Med. 2013; 5(185): 185ra62. https://dx.doi.org/10.1126/scitranslmed.3005402.
von Wolff M., Germeyer A., Liebenthron J., Korell M., Nawroth F. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part II: fertility preservation techniques. Arch. Gynecol. Obstet. 2018; 297(1): 257‐67. https://dx.doi.org/10.1007/s00404-017-4595-2.
von Wolff M., Montag M., Dittrich R., Denschlag D., Nawroth F., Lawrenz B. Fertility preservation in women - a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch. Gynecol. Obstet. 2011; 284(2): 427‐35. https://dx.doi.org/10.1007/s00404-011-1874-1.
Fatemi H.M., Garcia-Velasco J. Avoiding ovarian hyperstimulation syndrome with the use of gonadotropin-releasing hormone agonist trigger. Fertil. Steril. 2015; 103(4): 870‐3. https://dx.doi.org/10.1016/j.fertnstert.2015.02.004.
Zeng C., Shang J., Jin A.M., Wu P.L., Li X., Xue Q. The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study. Arch. Gynecol. Obstet. 2019; 300(1): 223‐33. https://dx.doi.org/10.1007/s00404-019-05163-3.
Turan V., Bedoschi G., Emirdar V., Moy F., Oktay K. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod. Sci. 2018; 25(1): 26‐32. https://dx.doi.org/10.1177/1933719117728800.

Received 12.08.2020

Accepted 20.10.2020

Irina Ye. Dmitrieva, PhD candidate, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology.
Tel.: +7(916)089-08-09. E-mail: nika06@inbox.ru. 4 Akademika Oparina str., Moscow, 117997, Russia.
Tatiana A. Nazarenko, Dr. Med. Sci., professor, Head of the Institute of Reproductive Medicine, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology. Tel.: +7(985)998-74-12. E-mail: t_nazarenko@oparina4.ru. 4 Akademika Oparina str., Moscow, 117997, Russia.
Svetlana V. Khokhlova, Dr. Med. Sci., Head of the Oncology Department of Anticancer drug therapy, V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology. Tel.: +7(903)170-98-02. E-mail: s_hohlova@oparina4.ru. 4 Akademika Oparina str., Moscow, 117997, Russia. 13

For citation: Dmitrieva I.E., Nazarenko T.A., Khokhlova S.V. Ovarian protection before gonadotoxic therapy is a problem of oncology and reproductive medicine.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 11: 13-19 (in Russian).
https://dx.doi.org/10.18565/aig.2020.11.13-19

Ovarian protection before gonadotoxic therapy is a problem of oncology and reproductive medicine

Dmitrieva I.E., Nazarenko T.A., Khokhlova S.V.

Keywords

References

About the Authors

Similar Articles